Contract drug manufacturing (CDMO) stocks
CDMO
What are Contract drug manufacturing (CDMO) stocks in Korea?
The Contract drug manufacturing (CDMO) theme on jonbur groups 24 Korean stocks listed on KOSPI and KOSDAQ, worth ₩127T in total. On Oct 27, 2026 the group moved down 3.11% (weighted by market value); the largest members are Samsung Biologics, Celltrion, Hanmi Pharm.
Key facts
- Stocks
- 24
- Total market value
- ₩127T
- Day's move
- −3.11%
- As of
- Oct 27, 2026
- Largest members
- Samsung Biologics, Celltrion, Hanmi Pharm
Earnings tracker · 2Q 2025
Past quarter
Combined, for the companies that have reported, vs the same quarter a year ago
| Company | Reported | Revenue | vs a year ago | Operating profit | vs a year ago | vs last quarter | Op. margin |
|---|---|---|---|---|---|---|---|
| Samsung Biologics | Aug 14 | ₩1.3T | +11.5% | ₩476B | +9.5% | −2.3% | 36.9%37.6% |
| Celltrion | Aug 14 | ₩961B | +9.9% | ₩242B | +234.5% | +62.3% | 25.2%8.3% |
| Hanmi Pharm | Aug 14 | ₩361B | −4.5% | ₩60B | +4.0% | +2.4% | 16.7%15.4% |
| SAM Chun Dang Pharm | Aug 14 | ₩57B | +3.7% | −₩1.1B | Turned to loss | Turned to loss | −1.9%3.9% |
| SK Bioscience | Aug 12 | ₩162B | +504.5% | −₩37B | Bigger loss | Bigger loss | −23.1%−74.5% |
| ST Pharm | Aug 14 | ₩68B | +53.1% | ₩13B | Turned to profit | +1,160.2% | 18.9%−6.9% |
| GC Biopharma | Aug 14 | ₩500B | +19.9% | ₩27B | +55.1% | +243.8% | 5.5%4.2% |
| Daewoong Pharma | Aug 14 | ₩405B | +12.5% | ₩58B | +36.7% | +49.5% | 14.3%11.7% |
| Chong Kun Dang Pharmaceutical | Aug 14 | ₩435B | +9.6% | ₩24B | −34.0% | +89.9% | 5.4%9.0% |
| Samyang Holdings | Aug 14 | ₩908B | −1.1% | ₩43B | −21.9% | +36.9% | 4.7%6.0% |
| IL Dong Pharmaceutical | Aug 14 | ₩138B | −9.0% | ₩596M | −41.4% | −85.8% | 0.4%0.7% |
| Dong-A ST | Aug 14 | ₩194B | +12.5% | −₩5.8B | Smaller loss | Bigger loss | −3.0%−3.5% |
| Prestige BioPharma | Sep 19 | ₩5.4M | +140.6% | −₩13M | Smaller loss | Smaller loss | −242.4%−684.9% |
| Inventage Lab | Aug 27 | ₩865M | +122.4% | −₩8.1B | Bigger loss | Bigger loss | −930.7%−1,013.9% |
| Huons | Aug 14 | ₩156B | +4.7% | ₩13B | +40.3% | +1.7% | 8.4%6.2% |
| Binex | Aug 14 | ₩45B | +41.5% | ₩1B | Turned to profit | +88.9% | 2.3%−26.3% |
| BNC Korea | Aug 14 | ₩25B | +8.4% | ₩1.6B | −64.1% | −58.0% | 6.5%19.6% |
| Kolon Life Science | Aug 14 | ₩53B | +32.2% | ₩1.3B | Turned to profit | +1,598.2% | 2.4%−16.0% |
| Prestige Biologics | Sep 19 | ₩8.9B | +194.5% | −₩9.7B | Smaller loss | Smaller loss | −109.5%−427.2% |
| GL Pharm Tech | Aug 14 | ₩8.4B | +20.0% | ₩182M | Turned to profit | +41.5% | 2.2%−7.0% |
| Aprogen Biologics | Aug 13 | ₩15B | −1.9% | −₩18B | Bigger loss | Bigger loss | −120.5%−79.9% |
| SeouLin Bioscience | Aug 14 | ₩16B | −18.0% | −₩332M | Turned to loss | Turned to loss | −2.0%1.0% |
| Proteina | Not yet | ||||||
| BioInfra Life Science | Not yet | ||||||
Single-quarter figures. Preliminary figures are the company's own early numbers and are replaced by the quarterly report when it's filed. Expected dates are around when each company reported a year ago.
Technical breadth
After the close on Oct 27, 2026- Above 20-day average
- 18.8%
- Above 60-day average
- 25%
- RSI above 70
- 0%
- RSI below 30
- 6.3%
- 52-week highs
- 0
- 52-week lows
- 4
Index gauge · Short term
Bearish
0 bullish, 2 neutral, 7 bearish
Index gauge · Medium term
Bearish
0 bullish, 1 neutral, 7 bearish
Technical read
The contract drug manufacturing (CDMO) theme covers 32 members, and only 18.8% of them trade above their 20-day average while 25% sit above their 60-day average. Breadth is weak on the trend measures, with no members at a 52-week high and 4 at a 52-week low, and the lowest member RSI reads 6.3 while the highest reads 0. The equal-weighted theme index is marked bearish on both short-term and medium-term readings, with an RSI of 38.8 and the index positioned below its cloud.
Written by AI from the indicator values above. Not advice.
Share of members, from each member's own indicators; the gauge reads an equal-weighted index of the members. Technical indicators describe past price and volume patterns. They are not predictions or recommendations.
Credit & macro
- MaturitiesOct 23, 202685GC Biopharma: ₩130bn of bonds due in the next 6 months vs ₩42bn cash₩130bn due within 12 months, from the bond filings so far; cash and cash equivalents as of 2026 H1.GC Biopharma
- MaturitiesOct 20, 202685SK Reit: ₩130bn of bonds due in the next 6 months vs ₩54bn cash₩350bn due within 12 months, from the bond filings so far; cash and cash equivalents as of 2025 FY.SK ReitSK hynixSK NetworksSK DiscoverySKCSK Telecom
Contract drug manufacturing (CDMO)
−0.40%CDMO
The CDMO (contract development and manufacturing organization) theme covers Korean companies that develop and manufacture pharmaceuticals, biologics, and related products on behalf of other drug companies, rather than selling their own branded medicines. Korean investors often group these firms together because they share a business model centered on large-scale bioproduction capacity, long-term client contracts, and exposure to the global biopharma outsourcing trend. The theme is also frequently linked to the broader Korean biotech sector, so its share prices tend to move alongside related names.
24 companies · 8 up · 3 flat · 13 down
- Traded value
- ₩294B
- Value vs 20-day average
- 0.89×
- Top gainer
- Proteina +5.04%
- Largest company
- Samsung Biologics ₩64T
Companies in this theme
| Company | Price | Daily | Traded value | Market cap | NPS |
|---|---|---|---|---|---|
Samsung Biologics207940 · KOSPI | ₩1,374,000 | −5.37% | ₩124B | ₩64T | 6.88% |
Celltrion068270 · KOSPI | ₩188,600 | −0.74% | ₩82B | ₩44T | 7.28% |
Hanmi Pharm128940 · KOSPI | ₩350,500 | −0.57% | ₩26B | ₩4.5T | 9.61% |
SAM Chun Dang Pharm000250 · KOSDAQ | ₩187,600 | −0.69% | ₩19B | ₩4.4T | 1.34% |
SK Bioscience302440 · KOSPI | ₩31,750 | −0.78% | ₩2.4B | ₩2.5T | 5.50% |
ST Pharm237690 · KOSDAQ | ₩80,400 | −9.15% | ₩21B | ₩1.7T | 5.77% |
GC Biopharma006280 · KOSPI | ₩129,100 | −0.39% | ₩2.1B | ₩1.5T | 6.68% |
Daewoong Pharma069620 · KOSPI | ₩99,100 | −1.49% | ₩2.2B | ₩1.1T | 10.30% |
Chong Kun Dang Pharmaceutical185750 · KOSPI | ₩61,300 | −0.97% | ₩1.5B | ₩846B | 6.34% |
Proteina468530 · KOSDAQ | ₩48,950 | +5.04% | ₩6.7B | ₩544B | 3.78% |
Samyang Holdings000070 · KOSPI | ₩52,000 | +0.78% | ₩206M | ₩404B | 2.68% |
IL Dong Pharmaceutical249420 · KOSPI | ₩12,650 | +2.02% | ₩915M | ₩400B | 2.30% |
Dong-A ST170900 · KOSPI | ₩34,900 | +2.95% | ₩1.2B | ₩340B | 4.78% |
Prestige BioPharma950210 · KOSPI | ₩5,050 | −0.20% | ₩362M | ₩303B | 0.15% |
Inventage Lab389470 · KOSDAQ | ₩22,800 | −0.22% | ₩1.1B | ₩303B | 0.31% |
Huons243070 · KOSDAQ | ₩17,190 | +2.02% | ₩298M | ₩206B | 0.71% |
Binex053030 · KOSDAQ | ₩6,070 | −2.25% | ₩465M | ₩198B | 2.17% |
BNC Korea256840 · KOSDAQ | ₩2,475 | 0.00% | ₩1.1B | ₩169B | — |
Kolon Life Science102940 · KOSDAQ | ₩12,760 | +0.79% | ₩596M | ₩167B | 0.50% |
Prestige Biologics334970 · KOSDAQ | ₩1,231 | −1.68% | ₩103M | ₩96B | — |
GL Pharm Tech204840 · KOSDAQ | ₩3,580 | 0.00% | ₩114M | ₩56B | — |
Aprogen Biologics003060 · KOSPI | ₩1,387 | +0.58% | ₩65M | ₩40B | 0.08% |
SeouLin Bioscience038070 · KOSDAQ | ₩3,625 | +0.83% | ₩19M | ₩34B | — |
BioInfra Life Science266470 · KONEX | ₩95 | 0.00% | ₩379,876 | ₩2.6B | — |
Source: KRX statistical information